Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ceftriaxone
Drug ID BADD_D00405
Description Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic.[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627]. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.[A215582]
Indications and Usage For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
Marketing Status Prescription; Discontinued
ATC Code J01DD04
DrugBank ID DB01212
KEGG ID D07659
MeSH ID D002443
PubChem ID 5479530
TTD Drug ID D07ACT
NDC Product Code 66794-214; 71205-593; 68071-4713; 44567-702; 66794-215; 70518-3355; 68180-633; 0143-9859; 50090-0945; 63187-435; 66794-213; 64679-702; 64679-701; 25021-106; 0143-9678; 68180-622; 25021-105; 66794-212; 25021-107; 0264-3155; 44567-700; 64679-703; 66794-211; 44567-703; 0143-9856; 71205-117; 0143-9858; 68071-4715; 72572-061; 68180-611; 68071-4304; 64679-983; 68071-4303; 44567-701; 0264-3153; 0143-9857; 63323-346; 68180-644; 72572-062; 50090-2628
Synonyms Ceftriaxone | Ceftriaxon | Cefatriaxone | Ceftriaxone, Disodium Salt, Hemiheptahydrate | Ceftrex | Ceftriaxon Curamed | Ceftriaxon Hexal | Ceftriaxona Andreu | Ceftriaxona LDP Torlan | Ceftriaxone Irex | Ceftriaxone Sodium | Ceftriaxone Sodium, Anhydrous | Anhydrous Ceftriaxone Sodium | Lendacin | Longacef | Longaceph | Ro13-9904 | Ro13 9904 | Ro139904 | Ro-13-9904 | Ro 13-9904 | Ro 13 9904 | Ro 139904 | Rocephin | Rocefalin | Rocephine | Rocefin | Tacex | Terbac | Ceftriaxone, Disodium Salt | Benaxona | Cefaxona
Chemical Information
Molecular Formula C18H18N8O7S3
CAS Registry Number 73384-59-5
SMILES CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Weight decreased13.15.01.005--
Wheezing22.03.01.0090.173620%
White blood cell count decreased13.01.06.012--
White blood cell count increased13.01.06.013--Not Available
Mental status changes19.07.01.0010.091916%Not Available
Tubulointerstitial nephritis20.05.02.0020.194045%Not Available
Cardiotoxicity12.03.01.007; 02.01.01.0020.030639%Not Available
Hydrothorax22.05.02.0040.020426%Not Available
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.0050.316600%Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Localised oedema14.05.06.009; 02.05.04.006; 08.01.07.0110.040852%
Brain oedema17.07.02.003; 12.01.10.0100.007993%
Brain death17.02.03.003; 08.04.01.0040.010657%Not Available
Emotional distress19.04.02.008--Not Available
Urethral haemorrhage20.07.01.003; 24.07.03.0060.020426%Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.005328%Not Available
Dysstasia17.02.02.0120.020426%Not Available
Urine calcium increased13.11.01.0390.020426%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.007993%Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.040852%Not Available
Generalised erythema23.03.06.0080.071490%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.030639%Not Available
Conjunctival hyperaemia06.04.01.0040.030639%Not Available
Haemodynamic instability24.03.02.0060.051065%Not Available
Eye pruritus06.04.05.0060.020426%Not Available
Pruritus generalised23.03.12.0030.102129%Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Protein urine present13.13.02.006--Not Available
Acquired haemophilia01.01.01.0020.005328%Not Available
The 15th Page    First    Pre   15 16 17 18    Next   Last    Total 18 Pages